STOCK TITAN

Cresco Labs Opens Sunnyside Dispensary in Wyomissing, Pennsylvania

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Cresco Labs, a leading U.S. cannabis company, has opened a new Sunnyside dispensary in Wyomissing, Pennsylvania, marking its fifth store in the state and 38th nationwide. The dispensary, spanning nearly 6,000 sq. feet, is strategically located for easy access to commuters and will serve patients with medical cards issued by the Pennsylvania Department of Health. Customers can shop a range of premium products, including flower, vape products, and topicals. Regular hours are Monday-Thursday and Sunday from 9AM to 6PM, and Friday-Saturday from 9AM to 7PM.

Positive
  • New Sunnyside dispensary opening increases Cresco Labs' footprint in Pennsylvania to five locations.
  • The dispensary offers a variety of premium cannabis products and accessories for consumers.
Negative
  • None.

CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38th nationwide.

Sunnyside Wyomissing opens Friday, October 22, marking Cresco Labs’ first store in the city of Reading and fifth location in Pennsylvania.

Sunnyside Wyomissing opens Friday, October 22, marking Cresco Labs’ first store in the city of Reading and fifth location in Pennsylvania.

Sunnyside Wyomissing is located at 208 N Park Rd. Unit #1. The nearly 6,000 sq. foot dispensary is across from The Knitting Mills, a redevelopment mixed-use business and retail campus, and minutes away from U.S. Route 222/US 422 for easy access to daily commuters.

The new store will offer premium quality products from Cresco Labs’ wholesale brands Cresco, Supply and Remedi, as well as other top brands. Products include flower; vape products like liquid live resin; concentrates; Rick Simpson Oil (RSO); topicals like lotion; capsules; and tinctures. It will also sell branded merchandise and accessories including vaporizers, vape batteries and more.

Sunnyside Wyomissing will serve patients with a medical card issued by the Pennsylvania Department of Health. Patients can place product orders online through the Sunnyside.shop website or visit Sunnyside to speak with wellness advisors for purchasing assistance. Regular store hours are Monday through Thursday and Sunday, 9AM to 6PM, and Friday and Saturday, 9AM to 7PM.

For more information about Sunnyside, visit www.sunnyside.shop.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Media:

Jason Erkes, Cresco Labs

Chief Communications Officer

press@crescolabs.com

Investors:

Jake Graves, Cresco Labs

Manager, Investor Relations

investors@crescolabs.com

For general Cresco Labs inquiries:

312-929-0993

info@crescolabs.com

Source: Cresco Labs Inc.

FAQ

What is the latest news about Cresco Labs (CRLBF)?

Cresco Labs has opened a new Sunnyside dispensary in Wyomissing, Pennsylvania, expanding its presence in the state.

When does the new Sunnyside dispensary in Wyomissing open?

The new Sunnyside dispensary in Wyomissing opens on Friday, October 22.

How many dispensaries does Cresco Labs (CRLBF) have now?

With the new addition, Cresco Labs now operates five dispensaries in Pennsylvania and 38 nationwide.

What products will be available at the new Sunnyside dispensary?

The dispensary will offer a range of products including flower, vape products, concentrates, and topicals.

What are the operating hours of the new Sunnyside dispensary?

The store will operate Monday to Thursday and Sunday from 9AM to 6PM, and Friday and Saturday from 9AM to 7PM.

CRESCO LABS INC

OTC:CRLBF

CRLBF Rankings

CRLBF Latest News

CRLBF Stock Data

374.59M
271.34M
0.66%
5.5%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Chicago